Post-treatment recovery patterns among patients with early-stage cancer who develop taxane-induced peripheral neuropathy (TIPN): SWOG S1714 (NCT03939481).
Rattachement africain : us, mx. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
12117 Background: The primary analysis of S1714 developed and validated a TIPN risk prediction model including 5 clinical risk factors. Recovery patterns of TIPN are not well described. Although some symptoms may improve with time, other symptoms may persist or worsen as a result of permanent nerve damage. We describe the incidence of TIPN over 3 years and report on the post-treatment patterns of TIPN in those individuals who report TIPN at the end of taxane treatment (EOT) as a secondary analysis of S1714. Methods: S1714 enrolled participants > 18 years with Stage I-III primary lung, breast, or ovarian cancer starting treatment with a taxane-based regimen for a planned duration of 8 to 18 weeks. Participants were followed over the course of 3 years and assessed for TIPN using the patient-reported EORTC QLQ-CIPN20, which is composed of 3 subscale scores reported from 0-100, with increasing scores representing worse TIPN. EOT TIPN was defined as an increase in the CIPN20 sensory subscale score of ≥8 points from pre-treatment to EOT. Results: Among 1336 enrolled patients, N = 1321 were evaluable: Median age 55.7 years (range 23-85), 98.9% female, 11.3% Black/4.5% Asian/10.5% Hispanic/Latino, 90.7% with breast cancer. Paclitaxel was administered to 60.3% and docetaxel to 39.7%; 98.4% planned to start treatment with full dose of taxane. EOT TIPN was reported in 553 participants (41.9%). We identified 3 patterns of TIPN in these 553 participants over the 3 year period using the EOT CIPN20 sensory score as the reference. Improvement in TIPN from EOT was seen in 268 participants (48.5%), defined as a decrease of ≥8 points from the EOT CIPN20 sensory score. Stable TIPN was seen in 187 participants (33.8%), defined as < 8 point increase or decrease from the EOT CIPN20 sensory score. Worsening of TIPN from EOT was seen in 98 participants (17.7%), defined as an increase of ≥8 points from the EOT CIPN20 sensory score. Of the 553 individuals with TIPN at EOT, 283 (51.2%) still had clinically meaningful TIPN at 3 years compared to the baseline pre-treatment CIPN20 sensory score (defined as increase in CIPN20 sensory score > 8 points from pre-treatment timepoint to final assessment). Conclusions: Among individuals experiencing TIPN at EOT, nearly half experienced clinically meaningful TIPN improvement but almost one fifth had worsening of TIPN by the final 3-year assessment. The identification of clinical and correlative risk factors for persistent or worsening TIPN after completion of taxane treatment will allow for more informed decision-making regarding the long-term risks of taxane treatment and prioritize selection of patients in the investigation of interventions for prevention and treatment of TIPN. Funding: NIH/NCI/NCORP grant UG1CA189974, The Hope Foundation for Cancer Research. Clinical trial information: NCT03939481 .
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Post-treatment recovery patterns among patients with early-stage cancer who develop taxane-induced peripheral neuropathy (TIPN): SWOG S1714 (NCT03939481).
- Date Crossref
- 01/06/2026
- Éditeur
- American Society of Clinical Oncology (ASCO)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Columbia University Irving Medical Center Herbert Irving Comprehensive Cancer Center pays non établi dans la noticeÉtablissement de santé
-
Fred Hutch Cancer Center pays non établi dans la noticeOrganisation à but non lucratif
-
University of Michigan pays non établi dans la noticeUniversité ou école supérieure
-
SWOG Cancer Research Network pays non établi dans la noticeStructure de recherche
-
St. Joseph’s Candler Hospital pays non établi dans la noticeÉtablissement de santé
-
Indiana University School of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Indiana University – Purdue University Indianapolis pays non établi dans la noticeUniversité ou école supérieure
-
St. Francis Medical Center pays non établi dans la noticeÉtablissement de santé
-
Saint Francis Medical Center pays non établi dans la noticeÉtablissement de santé
-
University Cancer and Blood Center pays non établi dans la noticeÉtablissement de santé
-
Hematology Oncology Consultants pays non établi dans la noticeÉtablissement de santé
-
Cone Health pays non établi dans la noticeÉtablissement de santé
Herbert Irving Comprehensive Cancer Center — Columbia University Irving Medical Center, Fred Hutch Cancer Center et University of Michigan, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.